Thursday, December 21, 2017

FLX Bio Picks Up $60M

South San Francisco-based FLX Bio, a biopharmaceuticals developer which is developing oral small-molecule drugs to activate the immune system against cancer, has raised $60M in a Series C funding. The funding came from GV (formerly Google Ventures), The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation. Brian Wong, M.D., Ph.D. is President and CEO of FLX Bio.